<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="case-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1322403</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Case Report: Identification of a novel <italic>LYN::LINC01900</italic> transcript with promyelocytic phenotype and <italic>TP53</italic> mutation in acute myeloid leukemia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Hu</surname>
<given-names>Chengjun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Dai</surname>
<given-names>Qiuxin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Ruiyi</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2424412"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Huanping</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Man</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1623157"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gu</surname>
<given-names>Kaili</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Jiangang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meng</surname>
<given-names>Wenjun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Ping</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xu</surname>
<given-names>Maozhong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Hematology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin</institution>, <addr-line>Jiangsu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Suzhou Jsuniwell Medical Laboratory</institution>, <addr-line>Suzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Sebastien Malinge, University of Western Australia, Australia</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Valeria Visconte, Cleveland Clinic, United States; Nelida Ines Noguera, University of Rome Tor Vergata, Italy</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Maozhong Xu, <email xlink:href="mailto:xumaozhongjy@163.cm">xumaozhongjy@163.cm</email>; Ping Chen, <email xlink:href="mailto:ping_chen@fujidabio.com">ping_chen@fujidabio.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1322403</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>10</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Hu, Dai, Zhang, Yang, Wang, Gu, Yang, Meng, Chen and Xu</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Hu, Dai, Zhang, Yang, Wang, Gu, Yang, Meng, Chen and Xu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells characterized by the abnormal proliferation of primitive and naive random cells in the bone marrow and peripheral blood. Acute promyelocytic leukemia (APL) is a type (AML-M3) of AML. Most patients with APL have the characteristic chromosomal translocation t(15; 17)(q22; q12), forming <italic>PML::RARA</italic> fusion. The occurrence and progression of AML are often accompanied by the emergence of gene fusions such as <italic>PML::RARA</italic>, <italic>CBF&#x3b2;::MYH11</italic>, and <italic>RUNX1::RUNX1T1</italic>, among others. Gene fusions are the main molecular biological abnormalities in acute leukemia, and all fusion genes act as crucial oncogenic factors in leukemia. Herein, we report the first case of <italic>LYN::LINC01900</italic> fusion transcript in AML with a promyelocytic phenotype and <italic>TP53</italic> mutation. Further studies should address whether new protein products may result from this fusion, as well as the biological function of these new products in disease occurrence and progression.</p>
</abstract>
<kwd-group>
<kwd>acute myeloid leukemia</kwd>
<kwd>LYN::LINC01900</kwd>
<kwd>promyelocytic phenotype</kwd>
<kwd>lncRNA fusion</kwd>
<kwd>mutation</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="36"/>
<page-count count="7"/>
<word-count count="2868"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Hematologic Malignancies</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Acute myeloid leukemia (AML), the most common acute leukemia (AL) among adults, is a highly heterogeneous hematological malignant tumor characterized by the proliferation and abnormal differentiation of immature cloned myeloid cells (<xref ref-type="bibr" rid="B1">1</xref>). Acute promyelocytic leukemia (APL) is a type (AML-M3) of AML. Most patients have a specific chromosomal translocation t(15;17)(q22;q12), forming <italic>PML::RARA</italic> gene fusion, whose protein product leads to cell differentiation arrest and insufficient apoptosis, which is the main molecular mechanism of APL occurrence (<xref ref-type="bibr" rid="B2">2</xref>). Initial, prompt diagnosis of APL is made through morphological and flow cytometric analyses. APL typically displays a distinct immunophenotype that lacks HLA-DR, CD34, and CD11B expression (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). However, similar immunophenotypic results have been observed in other AML types (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Thus, diagnosis of this APL-like AML has been a major challenge, and the lag between onset and diagnosis, as well as the resistance to the routine treatment of classical APL, results in an unfavorable prognosis (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>Many researchers have found that the onset of AML is usually accompanied by the appearance of different gene fusions such as <italic>CBFB::MYH11</italic>, <italic>PML::RARA</italic> and <italic>RUNX1::RUNX1T1 (</italic>
<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>). Gene fusions are the main molecular markers for prognostic stratification, minimal residual disease (MRD) monitoring, and targeted therapy in patients with AML (<xref ref-type="bibr" rid="B12">12</xref>). Furthermore, interactions between gene fusions and mutated genes can play a crucial role in the prognosis and recurrence of AML (<xref ref-type="bibr" rid="B13">13</xref>). With an increasing number of new fusions identified, hematopoietic malignancies have been shown to have greater molecular diversity, which may have important implications for sophisticated subtyping with molecular markers.</p>
<p>Long non-coding RNA (lncRNA) is defined as a non-coding RNA molecule with a length exceeding 200 nucleotides that was once considered as transcriptional &#x2018;junk&#x2019; DNA (<xref ref-type="bibr" rid="B14">14</xref>). However, with the development of molecular biology and sequencing technology, lncRNAs have been found to play an important role in tumor cell growth, apoptosis, invasion, and metastasis, as well as in the occurrence and progression of diseases (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Herein, we identified the <italic>LYN::LINC01900</italic> fusion transcript, which was predicted to express no fusion protein in an AML patient with <italic>TP53</italic> mutation. Moreover, clinical evidence showed that the bone marrow cells of the patient retained a promyelocytic phenotype; but there was no <italic>PML::RARA</italic> fusion. This indicated the potential function of this fusion in a new AML subtype. Hence, we hope that this case report on <italic>LYN::LINC01900</italic> transcript will provide a new perspective for understanding the occurrence and progression of AML.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Case description</title>
<p>A 76-year-old man was admitted to our hospital on October 12, 2022, with dizziness and fatigue for 6 months that had aggravated one month prior. The patient had a history of hypertension for over 20 years and type 2 diabetes mellitus and renal insufficiency for 8 and 2 years, respectively. After admission, a complete routine peripheral blood examination showed a white blood cell count of 1.26*10^9/L, red blood cell count of 1.44*10^12/L, monocyte cell count of 0.05*10^9/L, neutrophil cell count of 0.38*10^9/L, hemoglobin level of 51.0 g/L and platelet count of 32*10^9/L. The lymphocyte count was normal. The fibrinogen and D-dimer levels were 3.30 g/L (reference values [ref.] 2.00&#x2013;4.00 g/L) and 0.55 mg/L (ref. 0.00&#x2013;0.55 &#x3bc;g/mL), respectively. The prothrombin and activated partial thromboplastin time were 12.5 s (ref. 10.0&#x2013;14.0 s) and 27.2 s (ref. 25&#x2013;31.3 s), respectively.</p>
<p>To understand the cytological morphology, we observed the bone marrow smear of the patient and found that bone marrow cells proliferation and granulocyte proliferation were markedly high. The proportion of primitive granulocytes was 28%, and that of promyelocytes was as high as 56.5%. In addition, Wright Giemsa staining showed that erythrocyte and lymphocytic proliferation were inhibited (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). We further performed peroxidase staining test and found that the results of peroxidase staining of the bone marrow cell smear were positive (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>). Immunophenotyping by flow cytometry showed that the granulocyte population accounted for 58.5%, and these cells were positive for CD117, CD33, and CD38; weakly expressed CD13, CD4, CD64, and CD45; and negative for CD7, CD34, HLA-DR, CD10, CD20, CD19, CD14, CD2, CD15, CD11B, CD56, CD8, and CD3.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>
<bold>(A)</bold> Bone marrow smear of primitive granulocytes under a microscope. <bold>(B)</bold> Original granulocyte bone marrow smear after peroxidase staining. <bold>(C)</bold> FISH results of BM cells.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1322403-g001.tif"/>
</fig>
<p>Subsequently, the karyotype of the patient was analyzed. The results revealed a complex karyotype of 73&#x2013;80, XXY, +1, +2, &#x2013;3, +4, +6,?der (7), +8, &#x2013;9, &#x2013;9, &#x2013;11, &#x2013;11, &#x2013;12, +13, +14, +15, +15, +16, ?17, der (17)?i(17q), +19, +19, +20, +21, +22, +mar, inc[CP3]/45, X, &#x2013;Y[5]/46, XY[2]. FISH showed no evidence of <italic>PML::RARA</italic> fusion invloving t (15, 17)(q24; q21) but showed a higher fluorescence signal (normally 2 red and 2 green in single cell, now 4 red and 4 green), indicating gene amplification or +15,+15,+17,+17, which may originate from aberrant cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>). To further identify whether there were molecular variations involving essential genes functioning in hematopoietic malignancies, we used a 45-gene panel to detect gene mutations and a 53-gene panel to conduct a more comprehensive fusion screening using targeted RNA sequencing. Gene mutation results showed that <italic>TP53</italic> p.Arg273Cys was detected with a mutation allele frequency (MAF) of 81.4%. <italic>WT1</italic> p.Thr277Ile was detected, and the <italic>WT1</italic> mutation was suspected to be a germline mutation, based on the MAF of 67.10%. We used STAR software for bioinformatics analysis to predict fusion genes, with the reference genome being hg38. The <italic>LYN::LINC01900</italic> transcript, which is a fusion of <italic>LYN</italic> (NM_001111097.3) exon 8 with <italic>LINC01900</italic> (NC_000018.10) exon 2, was detected at a relative transcript expression level of 15.92% normalized to the reference gene <italic>ABL1</italic> (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A, B</bold>
</xref>). We then performed agarose gel electrophoresis on the amplified products (water as a blank control and healthy donor cDNA as a negative control). A band with a length of 230 bp was detected (100 bp of marker), while the reciprocal fusion <italic>LINC01900::LYN</italic> was not found, consistent with the RNA-targeted sequencing results (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>). Sanger sequencing of the targeted fusion product confirmed the presence of the <italic>LINC01900::LYN</italic> fusion transcript (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>
<bold>(A)</bold> Schematic diagram of the formation mechanism of <italic>LYN::LINC01900</italic> transcript. <bold>(B)</bold> Circos plot indicating novel fusions between <italic>LYN</italic> and <italic>LINC01900</italic>. <bold>(C)</bold> Electrophoresis of RT-PCR products from patient showing the <italic>LYN::LINC01900</italic> fusion transcript. <bold>(D)</bold> Partial nucleotide sequences surrounding the junctions of the <italic>LYN::LINC01900</italic> fusion transcript.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1322403-g002.tif"/>
</fig>
<p>The standard azacitidine + venetoclax therapy regimen, which consists of venetoclax (100 mg for day 1, 200 mg for day 2, and 400&#xa0;mg from days 3 to 28), PO QD, and azacitidine (75 mg/m<sup>2</sup> from&#xa0;days 1 to 7), subcutaneous injection (s.c.), was recommended&#xa0;according to the 2022 European LeukemiaNet (ELN) recommendations for the diagnosis and management of AML in adults (<xref ref-type="bibr" rid="B17">17</xref>). Considering the patient&#x2019;s renal dysfunction, the treatment was finally adjusted to venetoclax (100 mg on day 1 and 200 mg from days 2 to 21), PO QD, and azacitidine (75 mg/m<sup>2</sup> from days 1 to 7), s.c., supplemented with antiemetic treatment at the same time from November 02, 2022. The therapy regimen was adopted after communicating with the patient and their family members. The patient discharged due to economic reasons on November 09, 2022. After discharged, we conducted a follow-up finding that the patient continued the therapy of venetoclax (200 mg, PO QD) as we suggested until November 22, 2022. Unfortunately, no further clinical outcomes were monitored because the patient died of COVID-19 infection on December 2022 (<xref ref-type="fig" rid="f3">
<bold>Figure 3</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Timeline of the treatment.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1322403-g003.tif"/>
</fig>
</sec>
<sec id="s3" sec-type="discussion">
<label>3</label>
<title>Discussion</title>
<p>
<italic>LYN</italic>, which belongs to the <italic>ABL/Src</italic> tyrosine kinase family, is a proto-oncogene expressed in many hematopoietic diseases, including AML (<xref ref-type="bibr" rid="B18">18</xref>). The functional domains of <italic>LYN</italic> include four major parts: Src Homology 2 (SH2), SH3, proline-rich hinge region (P), and tyrosine kinase domain (<xref ref-type="bibr" rid="B19">19</xref>). The tyrosine kinase encoded by <italic>LYN</italic> is mainly expressed in hematopoietic cells, nervous tissue, liver, and adipose tissue (<xref ref-type="bibr" rid="B20">20</xref>). It also plays an important role in B cell-related signaling, mast cell development, and erythrocyte differentiation (<xref ref-type="bibr" rid="B21">21</xref>). Currently, gene rearrangements involving <italic>LYN</italic> are rarely observed in hematological diseases. There are a total of 6 reported cases of rearrangement involving <italic>LYN</italic> in hematological diseases, among which <italic>ETV6::LYN</italic> has been reported in 3 cases across different disease types including AML, primary myelofibrosis (PMF), and myeloproliferative neoplasms (MPN) (<xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B24">24</xref>). The clinical outcomes of the patients after receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) and/or chemotherapy showed two deaths and one not available. In a study from the children&#x2019;s oncology group, Shalini et&#xa0;al. reported the first <italic>GATAD2A::LYN</italic> transcript in B-cell acute lymphoblastic leukemia (B-ALL). However, no other relevant clinical data have been found in this paper (<xref ref-type="bibr" rid="B25">25</xref>). Yano et&#xa0;al. reported a <italic>NCOR1::LYN</italic> transcript accompanied with additional deletion of <italic>IKZF1</italic>, <italic>CDKN2A/2B</italic>, and <italic>BTG1</italic> in B-ALL (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Also in B-ALL, Dai et&#xa0;al. found a <italic>NCOR1::LYN</italic> transcript accompanied with deletion of <italic>IKZF1</italic> and <italic>CDKN2A</italic>. After receiving allo-HSCT and chemotherapy, the two patients received complete remission (CR) and complete molecular remission (CMR), respectively (<xref ref-type="bibr" rid="B28">28</xref>)(<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>The characteristics of the reported and our case with a <italic>LYN</italic> rearrangement.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Age (yrs)</th>
<th valign="middle" align="left">Gender</th>
<th valign="middle" align="left">Disease</th>
<th valign="middle" align="left">Initial WBC count (x 10<sup>9</sup>/L)</th>
<th valign="middle" align="left">Karyotype</th>
<th valign="middle" align="left">Gene fusion</th>
<th valign="middle" align="left">Additional genetic changes</th>
<th valign="middle" align="left">Therapy</th>
<th valign="middle" align="left">Clinical outcome</th>
<th valign="middle" align="left">Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">21</td>
<td valign="middle" align="left">male</td>
<td valign="middle" align="left">PMF</td>
<td valign="middle" align="left">25.5</td>
<td valign="middle" align="left">46XY, ins (12,8)(p13;q11q21)</td>
<td valign="middle" align="left">
<italic>ETV6::LYN</italic>
</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">Chemotherapy and hllo-HSCT</td>
<td valign="middle" align="left">Dead</td>
<td valign="middle" align="left">H Tanaka et&#xa0;al. (<xref ref-type="bibr" rid="B22">22</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">46</td>
<td valign="middle" align="left">male</td>
<td valign="middle" align="left">MPN</td>
<td valign="middle" align="left">17.2</td>
<td valign="middle" align="left">46,XY,der (8)inv(q12.1q21.1)t(8;12)(q12.1;p13),der(12)t(8;12)(q12.1;p13)[2]/47,sl,+der(8)inv(8)t(8;12)[5]/48,sdl1,+der(8)inv(8)t(8;12)[2]/46,XY[2]</td>
<td valign="middle" align="left">
<italic>ETV6::LYN</italic>
</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">Chemotherapy</td>
<td valign="middle" align="left">Dead</td>
<td valign="middle" align="left">N Telford et&#xa0;al. (<xref ref-type="bibr" rid="B23">23</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">41</td>
<td valign="middle" align="left">male</td>
<td valign="middle" align="left">AML</td>
<td valign="middle" align="left">16.1</td>
<td valign="middle" align="left">47,XY,der(1)ins(1;8)(p13;q12.1q24.21)t(1;12)(p13;p13.2),+8,der(8)ins(1;8)(p13;q12.1q24.21),der(12)t(1;12)(p13;p13.2)[19]/46,XY[1]</td>
<td valign="middle" align="left">
<italic>ETV6::LYN</italic>
</td>
<td valign="middle" align="left">no</td>
<td valign="middle" align="left">Chemotherapy and hllo-HSCT</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">Edmond S.K. Ma et&#xa0;al. (<xref ref-type="bibr" rid="B24">24</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">B-ALL</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">
<italic>GATAD2A::LYN</italic>
</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">not available</td>
<td valign="middle" align="left">Shalini C. Reshmi et&#xa0;al. (<xref ref-type="bibr" rid="B25">25</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">female</td>
<td valign="middle" align="left">B-ALL</td>
<td valign="middle" align="left">293</td>
<td valign="middle" align="left">no metaphase</td>
<td valign="middle" align="left">
<italic>NCOR1::LYN</italic>
</td>
<td valign="middle" align="left">
<italic>IKZF1</italic>, <italic>CDKN2A/2B</italic>, <italic>BTG1</italic> deletion</td>
<td valign="middle" align="left">Chemotherapy and hllo-HSCT</td>
<td valign="middle" align="left">CR</td>
<td valign="middle" align="left">Mio Yano et&#xa0;al. (<xref ref-type="bibr" rid="B26">26</xref>) and T Imamura et&#xa0;al. (<xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">male</td>
<td valign="middle" align="left">B-ALL</td>
<td valign="middle" align="left">883</td>
<td valign="middle" align="left">46,XY,t (8,17)(q12;p11.2[10]/48,idem,+der(17)t(9;17),+22/46,XY[1]) [9]/46, XY[9]</td>
<td valign="middle" align="left">
<italic>NCOR1::LYN</italic>
</td>
<td valign="middle" align="left">
<italic>IKZF1</italic>,<italic>CDKN2A</italic> deletion</td>
<td valign="middle" align="left">Chemotherapy and hllo-HSCT</td>
<td valign="middle" align="left">CMR</td>
<td valign="middle" align="left">Hai-Ping Dai et&#xa0;al. (<xref ref-type="bibr" rid="B28">28</xref>)</td>
</tr>
<tr>
<td valign="middle" align="left">76</td>
<td valign="middle" align="left">male</td>
<td valign="middle" align="left">AML</td>
<td valign="middle" align="left">1.26</td>
<td valign="middle" align="left">73&#x2013;80, XXY, +1, +2, &#x2013;3, +4, +6,?der (7), +8, &#x2013;9, &#x2013;9, &#x2013;11, &#x2013;11, &#x2013;12, +13, +14, +15, +15, +16, ?17, der (17)?i(17q), +19, +19, +20, +21, +22, +mar, inc[CP3]/45, X, &#x2013;Y[5]/46, XY</td>
<td valign="middle" align="left">
<italic>LYN::LINC01900</italic>
</td>
<td valign="middle" align="left">
<italic>TP53</italic> mutation</td>
<td valign="middle" align="left">Chemotherapy</td>
<td valign="middle" align="left">Dead</td>
<td valign="middle" align="left">The present case</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>A new rearrangement of <italic>LYN</italic> was found in this patient. This molecule was an lncRNA named <italic>LINC01900</italic>, lncRNAs have been reported to play a role in tumor cell growth, apoptosis, invasion, and metastasis, as well as in the occurrence and development of diseases by acting as chromatin-modifying factors, X chromosome-inactivating factors, enhancers, transcription regulating factors, and post-transcription regulating factors (<xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B32">32</xref>). <italic>LYN::LINC01900</italic> is formed through translocation, with <italic>LYN</italic> breaking at chr8:55953984:+ and <italic>LINC01900</italic> breaking at chr18:22043217:+. This transcript was an out-of-frame fusion protein that did not produce chimeric proteins. However, it may produce a truncated or possibly non-produced <italic>LYN</italic> protein, indicating the pathogenic role of haploid <italic>LYN</italic> dysfunction in&#xa0;this patient. In addition, no evidence of the reciprocal fusion transcript <italic>LINC01900::LYN</italic> was found. This indicates a more complicated translocation process that may be coupled with further transcriptional or post-transcriptional regulation.</p>
<p>Most patients with APL have a specific chromosomal translocation, t (15, 17)(q22; q12), forming the <italic>PML::RARA</italic> fusion gene. In our case, the cells retained a promyelocytic phenotype based on blast morphology and flow cytometric analysis. However, the FISH results of <italic>PML::RARA</italic> fusion gene in bone marrow of this patient suggested that there was no sign of t (15, 17)(q24; q21), but there were higher fluorescence signals indicating gene amplification. Studies have reported that APL-like AML is often accompanied by mutations in <italic>NPM1</italic> and/or <italic>FLT3</italic> mutation (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). However, no <italic>NPM1</italic> mutation was detected. We found a <italic>TP53</italic> (NM_000546.5) p.Arg273Cys mutation with a MAF of 81.4%. To the best of our knowledge, this is the first case of APL-like AML with <italic>TP53</italic> mutation, which is the most important tumor suppressor factor and is crucial for maintaining cellular genomic integrity. These findings may be used to identify new AML subtypes. Studies have indicated that AML with <italic>TP53</italic> mutations is often accompanied by complex karyotypes, which is consistent with the findings in our case (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Interactions between fusion and mutated genes can also play a crucial role in the prognosis and recurrence of AML (<xref ref-type="bibr" rid="B13">13</xref>). <italic>LYN::LINC01900</italic> may affect AML progression by interacting with <italic>TP53</italic>. Interestingly, we found that the expression of <italic>LYN</italic> was significantly reduced in AML patients with <italic>TP53</italic> mutation, compared to the AML patients without <italic>TP53</italic> mutation. The transcript per million (TPM) values from RNA-sequencing of the present case appear to be higher than those of the AML patients with <italic>TP53</italic> mutations, indicating that the <italic>LYN</italic> expression in this fusion may increase, which may cause the progression of diseases by regulating expression of other genes related to AML (<xref ref-type="fig" rid="f4">
<bold>Figure 4</bold>
</xref>). Further clinical data and reports need to be analyzed to improve this study in the future.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>The mRNA expression of <italic>LYN</italic> in the AML patients with/without <italic>TP53</italic> mutation, and the present case.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1322403-g004.tif"/>
</fig>
<p>Although the new fusion transcript was confirmed using different methods, no significant differences in expression of the fusion partner genes were observed. Moreover, no fusion protein was predicted because there may have been no termination codons. Further studies should address whether new protein products may result from this fusion, as well as the biological function of these new products in disease occurrence and progression.</p>
</sec>
<sec id="s4" sec-type="conclusions">
<label>4</label>
<title>Conclusions</title>
<p>Here, we report the case of a 76-year-old man with AML and a significantly higher proportion of promyelocytes. Wright Giemsa compound staining and peroxidase staining showed that erythrocyte and lymphocytic proliferation were inhibited, and the results of peroxidase staining of the bone marrow cell smear were positive. Immunophenotyping showed that the granulocyte population was positive for CD117, CD33, and CD38; weakly expressing CD13, CD4, CD64, and CD45; and negative for CD7, CD34, HLA-DR, CD10, CD20, CD19, CD14, CD2, CD15, CD11B, CD56, CD8, and CD3. Although a complex chromosomal karyotype was identified, FISH, qPCR, and RNA-targeted sequencing confirmed no evidence of <italic>PML::RARA</italic>. Additionally, <italic>TP53</italic> p.Arg273Cys was identified in the present case. Taken together, this patient was diagnosed with AML with <italic>TP53</italic> mutation and a promyelocyte phenotype. A novel fusion <italic>LYN::LINC01900</italic> was identified in this case. However, reciprocal fusion was not observed. Furthermore, the fusion was predicted to not express fusion proteins. Future studies should focus on the subgroups of fusions involving non-coding RNAs and their biological functions in hematopoietic malignancies. In conclusion, the <italic>LYN::LINC01900</italic> fusion transcript from the patient is the first such fusion to be reported on a global scale, to our knowledge. Here, we share this case report a novel <italic>LYN::LINC01900</italic> transcript with <italic>TP53</italic> mutation in APL-like AML to provide a new perspective for understanding the molecular diversity of AML.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Department of Hematology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>CH: Data curation, Writing &#x2013; review &amp; editing. QD: Data curation, Writing &#x2013; review &amp; editing. RZ: Data curation, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. HY: Data curation, Writing &#x2013; review &amp; editing. MW: Data curation, Writing &#x2013; review &amp; editing. KG: Data curation, Writing &#x2013; review &amp; editing. JY: Data curation, Writing &#x2013; review &amp; editing. WM: Data curation, Writing &#x2013; review &amp; editing. PC: Data curation, Methodology, Writing &#x2013; review &amp; editing. MX: Data curation, Methodology, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>This work was co-finished by Department of Hematology, The Affiliated Jiangyin Hospital of Southeast University Medical College; Suzhou Jsuniwell Medical Laboratory; and Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, China.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kantarjian</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kadia</surname> <given-names>T</given-names>
</name>
<name>
<surname>Dinardo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Daver</surname> <given-names>N</given-names>
</name>
<name>
<surname>Borthakur</surname> <given-names>G</given-names>
</name>
<name>
<surname>Jabbour</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute myeloid leukemia: current progress and future directions</article-title>. <source>Blood Cancer J</source> (<year>2021</year>) <volume>11</volume>(<issue>2</issue>):<elocation-id>41</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41408-021-00425-3</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Braekeleer</surname> <given-names>E</given-names>
</name>
<name>
<surname>Douet-Guilbert</surname> <given-names>N</given-names>
</name>
<name>
<surname>De Braekeleer</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>RARA fusion genes in acute promyelocytic leukemia: a review</article-title>. <source>Expert Rev Hematol</source> (<year>2014</year>) <volume>7</volume>(<issue>3</issue>):<page-range>347&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1586/17474086.2014.903794</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orfao</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chillon</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Bortoluci</surname> <given-names>AM</given-names>
</name>
<name>
<surname>L&#xf3;pez-Berges</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Garc&#xed;a-Sanz</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gonzalez</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The flow cytometric pattern Of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements</article-title>. <source>Haematologica</source> (<year>1999</year>) <volume>84</volume>(<issue>5</issue>):<page-range>405&#x2013;12</page-range>.</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paietta</surname> <given-names>E</given-names>
</name>
<name>
<surname>Andersen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gallagher</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bennett</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yunis</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cassileth</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study</article-title>. <source>Leukemia</source> (<year>1994</year>) <volume>8</volume>(<issue>7</issue>):<page-range>1108&#x2013;12</page-range>.</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Head</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Kopecky</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Appelbaum</surname> <given-names>FR</given-names>
</name>
<name>
<surname>Theil</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Grever</surname> <given-names>MR</given-names>
</name>
<etal/>
</person-group>. <article-title>HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as french-american-british acute myeloid leukemia-M3</article-title>. <source>Blood</source> (<year>1994</year>) <volume>84</volume>:<page-range>244&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.V84.1.244.244</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaleem</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Crawford</surname> <given-names>E</given-names>
</name>
<name>
<surname>Pathan</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Jasper</surname> <given-names>L</given-names>
</name>
<name>
<surname>Covinsky</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>LR</given-names>
</name>
<etal/>
</person-group>. <article-title>Flow Cytometric analysis of acute leukemias diagnostic utility and critical analysis of data</article-title>. <source>Arch Pathol Lab Med</source> (<year>2003</year>) <volume>127</volume>:<page-range>42&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5858/2003-127-42-FCAOA</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Current views on the genetic landscape and management of variant acute promyelocytic leukemia</article-title>. <source>biomark Res</source> (<year>2021</year>) <volume>9</volume>:<fpage>33</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40364-021-00284-x</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cicconi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Testi</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Montesinos</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rego</surname> <given-names>E</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants</article-title>. <source>Blood Cancer J</source> (<year>2021</year>) <volume>11</volume>:<fpage>167</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41408-021-00561-w</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tarl&#xe9;</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Hajra</surname> <given-names>A</given-names>
</name>
<name>
<surname>Claxton</surname> <given-names>DF</given-names>
</name>
<name>
<surname>Marlton</surname> <given-names>P</given-names>
</name>
<name>
<surname>Freedman</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia</article-title>. <source>Science</source> (<year>1993</year>) <volume>261</volume>(<issue>5124</issue>):<page-range>1041&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.8351518</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakizuka</surname> <given-names>A</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>WH</given-names> <suffix>Jr.</suffix>
</name>
<name>
<surname>Umesono</surname> <given-names>K</given-names>
</name>
<name>
<surname>Warrell</surname> <given-names>RP</given-names> <suffix>Jr</suffix>
</name>
<name>
<surname>Frankel</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Murty</surname> <given-names>VV</given-names>
</name>
<etal/>
</person-group>. <article-title>Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML</article-title>. <source>Cell</source> (<year>1991</year>) <volume>66</volume>(<issue>4</issue>):<page-range>663&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0092-8674(91)90112-c</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyoshi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kozu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Shimizu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Enomoto</surname> <given-names>K</given-names>
</name>
<name>
<surname>Maseki</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kaneko</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript</article-title>. <source>EMBO J</source> (<year>1993</year>) <volume>12</volume>(<issue>7</issue>):<page-range>2715&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/j.1460-2075.1993.tb05933.x</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>X</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>P</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center</article-title>. <source>Blood Cancer J</source> (<year>2021</year>) <volume>11</volume>(<issue>6</issue>):<fpage>112</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41408-021-00504-5</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>E</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns</article-title>. <source>Exp Hematol Oncol</source> (<year>2021</year>) <volume>10</volume>(<issue>1</issue>):<fpage>27</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40164-021-00207-4</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palazzo</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>ES</given-names>
</name>
</person-group>. <article-title>Non-coding RNA: what is functional and what is junk</article-title>? <source>Front Genet</source> (<year>2015</year>) <volume>6</volume>:<fpage>2</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gad.1800909</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Statello</surname> <given-names>L</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Huarte</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Gene regulation by long non-coding RNAs and its biological functions</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2021</year>) <volume>22</volume>(<issue>2</issue>):<fpage>96</fpage>&#x2013;<lpage>118</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-020-00315-9</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlevaro-fita</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rahim</surname> <given-names>A</given-names>
</name>
<name>
<surname>Guigo</surname> <given-names>R</given-names>
</name>
<name>
<surname>Vardy</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Cytoplasmic long noncoding RNAs are frequently bound to and degraded at ribosomes in human cells</article-title>. <source>RNA</source> (<year>2016</year>) <volume>22</volume>(<issue>6</issue>):<page-range>867&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1261/rna.053561.115</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D&#xf6;hner</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Appelbaum</surname> <given-names>FR</given-names>
</name>
<name>
<surname>Craddock</surname> <given-names>C</given-names>
</name>
<name>
<surname>DiNardo</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Dombret</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN</article-title>. <source>Blood</source> (<year>2022</year>) <volume>140</volume>(<issue>12</issue>):<page-range>1345&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.2022016867</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>The role of the tyrosine kinase Lyn in allergy and cancer</article-title>. <source>Mol Immunol</source> (<year>2021</year>) <volume>131</volume>:<page-range>121&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2020.12.028</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Harder</surname> <given-names>KW</given-names>
</name>
<name>
<surname>Huntington</surname> <given-names>ND</given-names>
</name>
<name>
<surname>Hibbs</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Tarlinton</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Lyn tyrosine kinase: accentuating the positive and the negative</article-title>. <source>Immunity</source> (<year>2005</year>) <volume>22</volume>:<fpage>9</fpage>&#x2013;<lpage>18</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1074-7613(04)00381-4</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dos Santos</surname> <given-names>C</given-names>
</name>
<name>
<surname>Demur</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bardet</surname> <given-names>V</given-names>
</name>
<name>
<surname>Prade-Houdellier</surname> <given-names>N</given-names>
</name>
<name>
<surname>Payrastre</surname> <given-names>B</given-names>
</name>
<name>
<surname>R&#xe9;cher</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>A critical role for Lyn in acute myeloid leukemia</article-title>. <source>Blood</source> (<year>2008</year>) <volume>111</volume>(<issue>4</issue>):<page-range>2269&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2007-04-082099</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamagna</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Defranco</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Lowell</surname> <given-names>CA</given-names>
</name>
</person-group>. <article-title>B cell-specific loss of Lyn kinase leads to autoimmunity</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>(<issue>3</issue>):<page-range>919&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1301979</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname> <given-names>H</given-names>
</name>
<name>
<surname>Takeuchi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Takeda</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sakai</surname> <given-names>S</given-names>
</name>
<name>
<surname>Abe</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ohwada</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis</article-title>. <source>Leukemia</source> (<year>2010</year>) <volume>24</volume>:<fpage>197</fpage>&#x2013;<lpage>200</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/leu.2009.167</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Telford</surname> <given-names>N</given-names>
</name>
<name>
<surname>Alexander</surname> <given-names>S</given-names>
</name>
<name>
<surname>McGinn</surname> <given-names>OJ</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wood</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Bloor</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion</article-title>. <source>Blood Cancer J</source> (<year>2016</year>) <volume>6</volume>:<fpage>e412</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/bcj.2016.11</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>ESK</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>TSK</given-names>
</name>
<name>
<surname>Au</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Ho</surname> <given-names>DN</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Ng</surname> <given-names>MHL</given-names>
</name>
<etal/>
</person-group>. <article-title>Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia</article-title>. <source>Cancer Genet</source> (<year>2017</year>) <volume>218-219</volume>:<page-range>15&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cancergen.2017.09.001</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reshmi</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Harvey</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Roberts</surname> <given-names>KG</given-names>
</name>
<name>
<surname>Stonerock</surname> <given-names>E</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jenkins</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Targetable kinase gene fusions in high-risk B-ALL: a study from the Children&#x2019;s Oncology Group</article-title>. <source>Blood</source> (<year>2017</year>) <volume>129</volume>:<page-range>3352&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2016-12-758979</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Imamura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Asai</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kiyokawa</surname> <given-names>N</given-names>
</name>
<name>
<surname>Nakabayashi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Matsumoto</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion</article-title>. <source>Br J Haematol</source> (<year>2015</year>) <volume>171</volume>:<page-range>813&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bjh.13757</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imamura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kiyokawa</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>M</given-names>
</name>
<name>
<surname>Imai</surname> <given-names>C</given-names>
</name>
<name>
<surname>Okamoto</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yano</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan</article-title>. <source>Blood Cancer J</source> (<year>2016</year>) <volume>6</volume>(<issue>5</issue>):<fpage>e419</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/bcj.2016.28</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>HP</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>CX</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Rapid molecular response to dasatinib in a pediatric relapsed acute lymphoblastic leukemia with NCOR1-LYN fusion</article-title>. <source>Front Oncol</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>359</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2020.00359</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>XK</given-names>
</name>
<name>
<surname>Xing</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>YF</given-names>
</name>
<name>
<surname>Shan</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct processing of lncRNAs contributes to non-conserved functions in stem cells</article-title>. <source>Cell</source> (<year>2020</year>) <volume>181</volume>(<issue>3</issue>):<fpage>621</fpage>&#x2013;<lpage>36.e22</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.03.006</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mumbach</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Granja</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Flynn</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Roake</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Satpathy</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Rubin</surname> <given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>HiChIRP reveals RNA-associated chromosome conformation</article-title>. <source>Nat Methods</source> (<year>2019</year>) <volume>16</volume>(<issue>6</issue>):<page-range>489&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41592-019-0407-x</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noh</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Abdelmohsen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yoon</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Panda</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Munk</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>HuR and GRSF1 modulate the nuclear export and mitochondrial localization of the lncRNA RMRP</article-title>. <source>Genes Dev</source> (<year>2016</year>) <volume>30</volume>(<issue>10</issue>):<page-range>1224&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gad.276022.115</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oleary</surname> <given-names>VB</given-names>
</name>
<name>
<surname>Ovespian</surname> <given-names>SV</given-names>
</name>
<name>
<surname>Carrascosa</surname> <given-names>LG</given-names>
</name>
<name>
<surname>Buske</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Radulovic</surname> <given-names>V</given-names>
</name>
<name>
<surname>Niyazi</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>PARTICLE, a triplex-forming long ncRNA, regulates locus-specific methylation in response to low-dose irradiation</article-title>. <source>Cell Rep</source> (<year>2015</year>) <volume>11</volume>(<issue>3</issue>):<page-range>474&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.043</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michael</surname> <given-names>P</given-names>
</name>
<name>
<surname>Brent</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia</article-title>. <source>Blood</source> (<year>2020</year>) <volume>136</volume>(<issue>12</issue>):<fpage>1467</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.2020007198</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arana Rosainz</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>N</given-names>
</name>
<name>
<surname>Wahed</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lelenwa</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Aakash</surname> <given-names>N</given-names>
</name>
<name>
<surname>Schaefer</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation</article-title>. <source>Int J Lab Hematol</source> (<year>2021</year>) <volume>43</volume>(<issue>2</issue>):<page-range>218&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/ijlh.13357</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Short</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Montalban-Bravo</surname> <given-names>G</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ning</surname> <given-names>J</given-names>
</name>
<name>
<surname>Franquiz</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Kanagal-Shamanna</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia</article-title>. <source>Blood Adv</source> (<year>2020</year>) <volume>4</volume>(<issue>22</issue>):<page-range>5681&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/bloodadvances.2020003120</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bowen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Groves</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Burnett</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Green</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis</article-title>. <source>Leukemia</source> (<year>2009</year>) <volume>23</volume>(<issue>1</issue>):<page-range>203&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/leu.2008.173</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>